AustralieFrV1, PubMed, Checkpoint, bibRecord, 002924

Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial.

Identifieur interne : 002924 ( PubMed/Checkpoint ); précédent : 002923; suivant : 002925

Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial.

Auteurs : Clemens Becker [Allemagne] ; Stephen R. Lord [Australie] ; Stephanie A. Studenski [États-Unis] ; Stuart J. Warden [États-Unis] ; Roger A. Fielding [États-Unis] ; Christopher P. Recknor [États-Unis] ; Marc C. Hochberg [États-Unis] ; Serge L. Ferrari [Suisse] ; Hubert Blain [France] ; Ellen F. Binder [États-Unis] ; Yves Rolland [France] ; Serge Poiraudeau [France] ; Charles T. Benson [États-Unis] ; Stephen L. Myers [États-Unis] ; Leijun Hu [États-Unis] ; Qasim I. Ahmad [États-Unis] ; Kelli R. Pacuch [États-Unis] ; Elisa V. Gomez [États-Unis] ; Olivier Benichou [France]

Source :

The lancet. Diabetes & endocrinology [ 2213-8595 ] ; 2015.

RBID : pubmed:26516121

Descripteurs français

KwdFr :
- Anticorps monoclonaux humanisés (administration et posologie), Anticorps monoclonaux humanisés (effets indésirables), Anticorps monoclonaux humanisés (usage thérapeutique), Chutes accidentelles, Démarche (), Faiblesse musculaire (traitement médicamenteux), Femelle, Force de préhension manuelle, Humains, Injections sous-cutanées, Muscles squelettiques (), Myostatine (antagonistes et inhibiteurs), Myostatine (immunologie), Mâle, Méthode en double aveugle, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus.
MESH :
- administration et posologie : Anticorps monoclonaux humanisés.
- antagonistes et inhibiteurs : Myostatine.
- effets indésirables : Anticorps monoclonaux humanisés.
- immunologie : Myostatine.
- traitement médicamenteux : Faiblesse musculaire.
- usage thérapeutique : Anticorps monoclonaux humanisés.
- Chutes accidentelles, Démarche, Femelle, Force de préhension manuelle, Humains, Injections sous-cutanées, Muscles squelettiques, Mâle, Méthode en double aveugle, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus.

English descriptors

KwdEn :
- Accidental Falls, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized (administration & dosage), Antibodies, Monoclonal, Humanized (adverse effects), Antibodies, Monoclonal, Humanized (therapeutic use), Double-Blind Method, Female, Gait (drug effects), Hand Strength, Humans, Injections, Subcutaneous, Male, Muscle Weakness (drug therapy), Muscle, Skeletal (drug effects), Myostatin (antagonists & inhibitors), Myostatin (immunology), Treatment Outcome.
MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Humanized.
- chemical , adverse effects : Antibodies, Monoclonal, Humanized.
- chemical , antagonists & inhibitors : Myostatin.
- chemical , immunology : Myostatin.
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized.
- drug effects : Gait, Muscle, Skeletal.
- drug therapy : Muscle Weakness.
- Accidental Falls, Aged, Aged, 80 and over, Double-Blind Method, Female, Hand Strength, Humans, Injections, Subcutaneous, Male, Treatment Outcome.

Abstract

Myostatin inhibits skeletal muscle growth. The humanised monoclonal antibody LY2495655 (LY) binds and neutralises myostatin. We aimed to test whether LY increases appendicular lean body mass (aLBM) and improves physical performance in older individuals who have had recent falls and low muscle strength and power.

DOI: 10.1016/S2213-8587(15)00298-3
PubMed: 26516121

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 002660
to stream PubMed, to step Curation: 002591

Links to Exploration step

pubmed:26516121

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial.</title>
<author><name sortKey="Becker, Clemens" sort="Becker, Clemens" uniqKey="Becker C" first="Clemens" last="Becker">Clemens Becker</name>
<affiliation wicri:level="3"><nlm:affiliation>Robert-Bosch-Krankenhaus, Stuttgart, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Robert-Bosch-Krankenhaus, Stuttgart</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Stuttgart</region>
<settlement type="city">Stuttgart</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lord, Stephen R" sort="Lord, Stephen R" uniqKey="Lord S" first="Stephen R" last="Lord">Stephen R. Lord</name>
<affiliation wicri:level="1"><nlm:affiliation>NeuRA, UNSW, Sydney, NSW, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>NeuRA, UNSW, Sydney, NSW</wicri:regionArea>
<wicri:noRegion>NSW</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Studenski, Stephanie A" sort="Studenski, Stephanie A" uniqKey="Studenski S" first="Stephanie A" last="Studenski">Stephanie A. Studenski</name>
<affiliation wicri:level="4"><nlm:affiliation>University of Pittsburgh, Pittsburgh, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pittsburgh, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
<author><name sortKey="Warden, Stuart J" sort="Warden, Stuart J" uniqKey="Warden S" first="Stuart J" last="Warden">Stuart J. Warden</name>
<affiliation wicri:level="2"><nlm:affiliation>School of Health and Rehabilitation Sciences, Indiana University, Indianapolis, IN, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>School of Health and Rehabilitation Sciences, Indiana University, Indianapolis, IN</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fielding, Roger A" sort="Fielding, Roger A" uniqKey="Fielding R" first="Roger A" last="Fielding">Roger A. Fielding</name>
<affiliation wicri:level="2"><nlm:affiliation>Nutrition, Exercise Physiology, and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Nutrition, Exercise Physiology, and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Recknor, Christopher P" sort="Recknor, Christopher P" uniqKey="Recknor C" first="Christopher P" last="Recknor">Christopher P. Recknor</name>
<affiliation wicri:level="2"><nlm:affiliation>United Osteoporosis Centers, Gainesville, GA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>United Osteoporosis Centers, Gainesville, GA</wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hochberg, Marc C" sort="Hochberg, Marc C" uniqKey="Hochberg M" first="Marc C" last="Hochberg">Marc C. Hochberg</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Maryland School of Medicine, Baltimore, MD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Maryland School of Medicine, Baltimore, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ferrari, Serge L" sort="Ferrari, Serge L" uniqKey="Ferrari S" first="Serge L" last="Ferrari">Serge L. Ferrari</name>
<affiliation wicri:level="1"><nlm:affiliation>Geneva University Hospital, Geneva, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Geneva University Hospital, Geneva</wicri:regionArea>
<wicri:noRegion>Geneva</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Blain, Hubert" sort="Blain, Hubert" uniqKey="Blain H" first="Hubert" last="Blain">Hubert Blain</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine and Geriatrics, Montpellier University Hospital, M2H, MACVIA-LR, Montpellier University, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Internal Medicine and Geriatrics, Montpellier University Hospital, M2H, MACVIA-LR, Montpellier University, Montpellier</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Binder, Ellen F" sort="Binder, Ellen F" uniqKey="Binder E" first="Ellen F" last="Binder">Ellen F. Binder</name>
<affiliation wicri:level="4"><nlm:affiliation>Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Washington University School of Medicine, St Louis, MO</wicri:regionArea>
<placeName><region type="state">Missouri (État)</region>
<settlement type="city">Saint-Louis (Missouri)</settlement>
</placeName>
<orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName>
</affiliation>
</author>
<author><name sortKey="Rolland, Yves" sort="Rolland, Yves" uniqKey="Rolland Y" first="Yves" last="Rolland">Yves Rolland</name>
<affiliation wicri:level="3"><nlm:affiliation>Gérontopôle de Toulouse, Centre Hospitalo‑Universitaire de Toulouse, and INSERM 1027, Toulouse, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Gérontopôle de Toulouse, Centre Hospitalo‑Universitaire de Toulouse, and INSERM 1027, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Poiraudeau, Serge" sort="Poiraudeau, Serge" uniqKey="Poiraudeau S" first="Serge" last="Poiraudeau">Serge Poiraudeau</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Physical Rehabilitation for Musculoskeletal and Spinal Disorders, Cochin Hospital, Paris, France; Paris Descartes University, Paris, France; INSERM U1153, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Physical Rehabilitation for Musculoskeletal and Spinal Disorders, Cochin Hospital, Paris, France; Paris Descartes University, Paris, France; INSERM U1153, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Benson, Charles T" sort="Benson, Charles T" uniqKey="Benson C" first="Charles T" last="Benson">Charles T. Benson</name>
<affiliation wicri:level="2"><nlm:affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Eli Lilly and Company, Indianapolis, IN</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Myers, Stephen L" sort="Myers, Stephen L" uniqKey="Myers S" first="Stephen L" last="Myers">Stephen L. Myers</name>
<affiliation wicri:level="2"><nlm:affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Eli Lilly and Company, Indianapolis, IN</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hu, Leijun" sort="Hu, Leijun" uniqKey="Hu L" first="Leijun" last="Hu">Leijun Hu</name>
<affiliation wicri:level="2"><nlm:affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Eli Lilly and Company, Indianapolis, IN</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ahmad, Qasim I" sort="Ahmad, Qasim I" uniqKey="Ahmad Q" first="Qasim I" last="Ahmad">Qasim I. Ahmad</name>
<affiliation wicri:level="2"><nlm:affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Eli Lilly and Company, Indianapolis, IN</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pacuch, Kelli R" sort="Pacuch, Kelli R" uniqKey="Pacuch K" first="Kelli R" last="Pacuch">Kelli R. Pacuch</name>
<affiliation wicri:level="2"><nlm:affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Eli Lilly and Company, Indianapolis, IN</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gomez, Elisa V" sort="Gomez, Elisa V" uniqKey="Gomez E" first="Elisa V" last="Gomez">Elisa V. Gomez</name>
<affiliation wicri:level="2"><nlm:affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Eli Lilly and Company, Indianapolis, IN</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Benichou, Olivier" sort="Benichou, Olivier" uniqKey="Benichou O" first="Olivier" last="Benichou">Olivier Benichou</name>
<affiliation wicri:level="1"><nlm:affiliation>Eli Lilly and Company, Neuilly, France. Electronic address: benichou_olivier@lilly.com.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Eli Lilly and Company, Neuilly</wicri:regionArea>
<wicri:noRegion>Neuilly</wicri:noRegion>
<wicri:noRegion>Neuilly</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:26516121</idno>
<idno type="pmid">26516121</idno>
<idno type="doi">10.1016/S2213-8587(15)00298-3</idno>
<idno type="wicri:Area/PubMed/Corpus">002660</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002660</idno>
<idno type="wicri:Area/PubMed/Curation">002591</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002591</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002591</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002591</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial.</title>
<author><name sortKey="Becker, Clemens" sort="Becker, Clemens" uniqKey="Becker C" first="Clemens" last="Becker">Clemens Becker</name>
<affiliation wicri:level="3"><nlm:affiliation>Robert-Bosch-Krankenhaus, Stuttgart, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Robert-Bosch-Krankenhaus, Stuttgart</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Stuttgart</region>
<settlement type="city">Stuttgart</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lord, Stephen R" sort="Lord, Stephen R" uniqKey="Lord S" first="Stephen R" last="Lord">Stephen R. Lord</name>
<affiliation wicri:level="1"><nlm:affiliation>NeuRA, UNSW, Sydney, NSW, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>NeuRA, UNSW, Sydney, NSW</wicri:regionArea>
<wicri:noRegion>NSW</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Studenski, Stephanie A" sort="Studenski, Stephanie A" uniqKey="Studenski S" first="Stephanie A" last="Studenski">Stephanie A. Studenski</name>
<affiliation wicri:level="4"><nlm:affiliation>University of Pittsburgh, Pittsburgh, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pittsburgh, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
<author><name sortKey="Warden, Stuart J" sort="Warden, Stuart J" uniqKey="Warden S" first="Stuart J" last="Warden">Stuart J. Warden</name>
<affiliation wicri:level="2"><nlm:affiliation>School of Health and Rehabilitation Sciences, Indiana University, Indianapolis, IN, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>School of Health and Rehabilitation Sciences, Indiana University, Indianapolis, IN</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fielding, Roger A" sort="Fielding, Roger A" uniqKey="Fielding R" first="Roger A" last="Fielding">Roger A. Fielding</name>
<affiliation wicri:level="2"><nlm:affiliation>Nutrition, Exercise Physiology, and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Nutrition, Exercise Physiology, and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Recknor, Christopher P" sort="Recknor, Christopher P" uniqKey="Recknor C" first="Christopher P" last="Recknor">Christopher P. Recknor</name>
<affiliation wicri:level="2"><nlm:affiliation>United Osteoporosis Centers, Gainesville, GA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>United Osteoporosis Centers, Gainesville, GA</wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hochberg, Marc C" sort="Hochberg, Marc C" uniqKey="Hochberg M" first="Marc C" last="Hochberg">Marc C. Hochberg</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Maryland School of Medicine, Baltimore, MD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Maryland School of Medicine, Baltimore, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ferrari, Serge L" sort="Ferrari, Serge L" uniqKey="Ferrari S" first="Serge L" last="Ferrari">Serge L. Ferrari</name>
<affiliation wicri:level="1"><nlm:affiliation>Geneva University Hospital, Geneva, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Geneva University Hospital, Geneva</wicri:regionArea>
<wicri:noRegion>Geneva</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Blain, Hubert" sort="Blain, Hubert" uniqKey="Blain H" first="Hubert" last="Blain">Hubert Blain</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine and Geriatrics, Montpellier University Hospital, M2H, MACVIA-LR, Montpellier University, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Internal Medicine and Geriatrics, Montpellier University Hospital, M2H, MACVIA-LR, Montpellier University, Montpellier</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Binder, Ellen F" sort="Binder, Ellen F" uniqKey="Binder E" first="Ellen F" last="Binder">Ellen F. Binder</name>
<affiliation wicri:level="4"><nlm:affiliation>Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Washington University School of Medicine, St Louis, MO</wicri:regionArea>
<placeName><region type="state">Missouri (État)</region>
<settlement type="city">Saint-Louis (Missouri)</settlement>
</placeName>
<orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName>
</affiliation>
</author>
<author><name sortKey="Rolland, Yves" sort="Rolland, Yves" uniqKey="Rolland Y" first="Yves" last="Rolland">Yves Rolland</name>
<affiliation wicri:level="3"><nlm:affiliation>Gérontopôle de Toulouse, Centre Hospitalo‑Universitaire de Toulouse, and INSERM 1027, Toulouse, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Gérontopôle de Toulouse, Centre Hospitalo‑Universitaire de Toulouse, and INSERM 1027, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Poiraudeau, Serge" sort="Poiraudeau, Serge" uniqKey="Poiraudeau S" first="Serge" last="Poiraudeau">Serge Poiraudeau</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Physical Rehabilitation for Musculoskeletal and Spinal Disorders, Cochin Hospital, Paris, France; Paris Descartes University, Paris, France; INSERM U1153, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Physical Rehabilitation for Musculoskeletal and Spinal Disorders, Cochin Hospital, Paris, France; Paris Descartes University, Paris, France; INSERM U1153, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Benson, Charles T" sort="Benson, Charles T" uniqKey="Benson C" first="Charles T" last="Benson">Charles T. Benson</name>
<affiliation wicri:level="2"><nlm:affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Eli Lilly and Company, Indianapolis, IN</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Myers, Stephen L" sort="Myers, Stephen L" uniqKey="Myers S" first="Stephen L" last="Myers">Stephen L. Myers</name>
<affiliation wicri:level="2"><nlm:affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Eli Lilly and Company, Indianapolis, IN</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hu, Leijun" sort="Hu, Leijun" uniqKey="Hu L" first="Leijun" last="Hu">Leijun Hu</name>
<affiliation wicri:level="2"><nlm:affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Eli Lilly and Company, Indianapolis, IN</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ahmad, Qasim I" sort="Ahmad, Qasim I" uniqKey="Ahmad Q" first="Qasim I" last="Ahmad">Qasim I. Ahmad</name>
<affiliation wicri:level="2"><nlm:affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Eli Lilly and Company, Indianapolis, IN</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pacuch, Kelli R" sort="Pacuch, Kelli R" uniqKey="Pacuch K" first="Kelli R" last="Pacuch">Kelli R. Pacuch</name>
<affiliation wicri:level="2"><nlm:affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Eli Lilly and Company, Indianapolis, IN</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gomez, Elisa V" sort="Gomez, Elisa V" uniqKey="Gomez E" first="Elisa V" last="Gomez">Elisa V. Gomez</name>
<affiliation wicri:level="2"><nlm:affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Eli Lilly and Company, Indianapolis, IN</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Benichou, Olivier" sort="Benichou, Olivier" uniqKey="Benichou O" first="Olivier" last="Benichou">Olivier Benichou</name>
<affiliation wicri:level="1"><nlm:affiliation>Eli Lilly and Company, Neuilly, France. Electronic address: benichou_olivier@lilly.com.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Eli Lilly and Company, Neuilly</wicri:regionArea>
<wicri:noRegion>Neuilly</wicri:noRegion>
<wicri:noRegion>Neuilly</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">The lancet. Diabetes & endocrinology</title>
<idno type="eISSN">2213-8595</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Accidental Falls</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antibodies, Monoclonal, Humanized (administration & dosage)</term>
<term>Antibodies, Monoclonal, Humanized (adverse effects)</term>
<term>Antibodies, Monoclonal, Humanized (therapeutic use)</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Gait (drug effects)</term>
<term>Hand Strength</term>
<term>Humans</term>
<term>Injections, Subcutaneous</term>
<term>Male</term>
<term>Muscle Weakness (drug therapy)</term>
<term>Muscle, Skeletal (drug effects)</term>
<term>Myostatin (antagonists & inhibitors)</term>
<term>Myostatin (immunology)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps monoclonaux humanisés (administration et posologie)</term>
<term>Anticorps monoclonaux humanisés (effets indésirables)</term>
<term>Anticorps monoclonaux humanisés (usage thérapeutique)</term>
<term>Chutes accidentelles</term>
<term>Démarche ()</term>
<term>Faiblesse musculaire (traitement médicamenteux)</term>
<term>Femelle</term>
<term>Force de préhension manuelle</term>
<term>Humains</term>
<term>Injections sous-cutanées</term>
<term>Muscles squelettiques ()</term>
<term>Myostatine (antagonistes et inhibiteurs)</term>
<term>Myostatine (immunologie)</term>
<term>Mâle</term>
<term>Méthode en double aveugle</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Myostatin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Myostatin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Myostatine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Gait</term>
<term>Muscle, Skeletal</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Muscle Weakness</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Myostatine</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Faiblesse musculaire</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Accidental Falls</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Hand Strength</term>
<term>Humans</term>
<term>Injections, Subcutaneous</term>
<term>Male</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Chutes accidentelles</term>
<term>Démarche</term>
<term>Femelle</term>
<term>Force de préhension manuelle</term>
<term>Humains</term>
<term>Injections sous-cutanées</term>
<term>Muscles squelettiques</term>
<term>Mâle</term>
<term>Méthode en double aveugle</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Myostatin inhibits skeletal muscle growth. The humanised monoclonal antibody LY2495655 (LY) binds and neutralises myostatin. We aimed to test whether LY increases appendicular lean body mass (aLBM) and improves physical performance in older individuals who have had recent falls and low muscle strength and power.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26516121</PMID>
<DateCreated><Year>2015</Year>
<Month>11</Month>
<Day>23</Day>
</DateCreated>
<DateCompleted><Year>2016</Year>
<Month>09</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>11</Month>
<Day>23</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-8595</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>3</Volume>
<Issue>12</Issue>
<PubDate><Year>2015</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>The lancet. Diabetes & endocrinology</Title>
<ISOAbbreviation>Lancet Diabetes Endocrinol</ISOAbbreviation>
</Journal>
<ArticleTitle>Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial.</ArticleTitle>
<Pagination><MedlinePgn>948-57</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/S2213-8587(15)00298-3</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S2213-8587(15)00298-3</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Myostatin inhibits skeletal muscle growth. The humanised monoclonal antibody LY2495655 (LY) binds and neutralises myostatin. We aimed to test whether LY increases appendicular lean body mass (aLBM) and improves physical performance in older individuals who have had recent falls and low muscle strength and power.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">In this proof-of-concept, randomised, placebo-controlled, double-blind, parallel, multicentre, phase 2 study, we recruited patients aged 75 years or older who had fallen in the past year from 21 investigator sites across Argentina, Australia, France, Germany, Sweden, and the USA. Eligible patients had low performance on hand grip strength and chair rise tests, tested with the procedure described by Guralnik and colleagues. Participants were stratified by country, age, hand grip strength, and performance on the chair rise test, and were randomly assigned (1:1) by a computer-generated random sequence to receive subcutaneous injections of placebo or 315 mg LY at weeks 0 (randomisation visit), 4, 8, 12, 16, and 20, followed by 16 weeks observation. The primary outcome was change in aLBM from baseline to 24 weeks. We measured physical performance as secondary outcomes (four-step stair climbing time, usual gait speed, and time to rise five times from a chair without arms, or with arms for participants unable to do it without arms) and exploratory outcomes (12-step stair climbing test, 6-min walking distance, fast gait speed, hand grip strength, and isometric leg extension strength). Efficacy analyses included all randomly assigned patients who received at least one dose and had a baseline and at least one subsequent measure. The primary analysis and all other tests of treatment effect (except physical performance tests) were done at a two-sided alpha level of 0·05. Tests of treatment effect on physical performance tests were done at a pre-specified two-sided alpha level of 0·1. This trial is registered with ClinicalTrials.gov, number NCT01604408.</AbstractText>
<AbstractText Label="FINDINGS" NlmCategory="RESULTS">Between June 19, 2012, and Dec 12, 2013, we screened 365 patients. 99 were randomly assigned to receive placebo and 102 to receive LY. Treatment was completed in 85 (86%) of patients given placebo and in 82 (80%) given LY. At 24 weeks, the least-squares mean change in aLBM was -0·123 kg (95% CI -0·287 to 0·040) in the placebo group and 0·303 kg (0·135 to 0·470) in the LY group, a difference of 0·43 kg (95% CI 0·192 to 0·660; p<0·0001). Stair climbing time (four-step and 12-step tests), chair rise with arms, and fast gait speed improved significantly from baseline to week 24 with differences between LY and placebo of respectively -0·46 s (p=0·093), -1·28 s (p=0·011), -4·15 s (p=0·054), and 0·05 m/s (p=0·088). No effect was detected for other performance-based measures. Injection site reactions were recorded in nine (9%) patients given placebo and in 31 (30%) patients given LY (p<0·0001), and were generally mild, and led to treatment discontinuation in two patients given LY.</AbstractText>
<AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Our findings show LY treatment increases lean mass and might improve functional measures of muscle power. Although additional studies are needed to confirm these results, our data suggest LY should be tested for its potential ability to reduce the risk of falls or physical dependency in older weak fallers.</AbstractText>
<AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Eli Lilly and Company.</AbstractText>
<CopyrightInformation>Copyright © 2015 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Becker</LastName>
<ForeName>Clemens</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Robert-Bosch-Krankenhaus, Stuttgart, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lord</LastName>
<ForeName>Stephen R</ForeName>
<Initials>SR</Initials>
<AffiliationInfo><Affiliation>NeuRA, UNSW, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Studenski</LastName>
<ForeName>Stephanie A</ForeName>
<Initials>SA</Initials>
<AffiliationInfo><Affiliation>University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Warden</LastName>
<ForeName>Stuart J</ForeName>
<Initials>SJ</Initials>
<AffiliationInfo><Affiliation>School of Health and Rehabilitation Sciences, Indiana University, Indianapolis, IN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fielding</LastName>
<ForeName>Roger A</ForeName>
<Initials>RA</Initials>
<AffiliationInfo><Affiliation>Nutrition, Exercise Physiology, and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Recknor</LastName>
<ForeName>Christopher P</ForeName>
<Initials>CP</Initials>
<AffiliationInfo><Affiliation>United Osteoporosis Centers, Gainesville, GA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hochberg</LastName>
<ForeName>Marc C</ForeName>
<Initials>MC</Initials>
<AffiliationInfo><Affiliation>University of Maryland School of Medicine, Baltimore, MD, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ferrari</LastName>
<ForeName>Serge L</ForeName>
<Initials>SL</Initials>
<AffiliationInfo><Affiliation>Geneva University Hospital, Geneva, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Blain</LastName>
<ForeName>Hubert</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Department of Internal Medicine and Geriatrics, Montpellier University Hospital, M2H, MACVIA-LR, Montpellier University, Montpellier, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Binder</LastName>
<ForeName>Ellen F</ForeName>
<Initials>EF</Initials>
<AffiliationInfo><Affiliation>Washington University School of Medicine, St Louis, MO, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rolland</LastName>
<ForeName>Yves</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Gérontopôle de Toulouse, Centre Hospitalo‑Universitaire de Toulouse, and INSERM 1027, Toulouse, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Poiraudeau</LastName>
<ForeName>Serge</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Physical Rehabilitation for Musculoskeletal and Spinal Disorders, Cochin Hospital, Paris, France; Paris Descartes University, Paris, France; INSERM U1153, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Benson</LastName>
<ForeName>Charles T</ForeName>
<Initials>CT</Initials>
<AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Myers</LastName>
<ForeName>Stephen L</ForeName>
<Initials>SL</Initials>
<AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hu</LastName>
<ForeName>Leijun</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ahmad</LastName>
<ForeName>Qasim I</ForeName>
<Initials>QI</Initials>
<AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pacuch</LastName>
<ForeName>Kelli R</ForeName>
<Initials>KR</Initials>
<AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gomez</LastName>
<ForeName>Elisa V</ForeName>
<Initials>EV</Initials>
<AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Benichou</LastName>
<ForeName>Olivier</ForeName>
<Initials>O</Initials>
<AffiliationInfo><Affiliation>Eli Lilly and Company, Neuilly, France. Electronic address: benichou_olivier@lilly.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><CollectiveName>STEADY Group</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList><AccessionNumber>NCT01604408</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>10</Month>
<Day>27</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Lancet Diabetes Endocrinol</MedlineTA>
<NlmUniqueID>101618821</NlmUniqueID>
<ISSNLinking>2213-8587</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000607476">LY2495655</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C525911">MSTN protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D055435">Myostatin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Diabetes Endocrinol. 2015 Dec;3(12):917-8</RefSource>
<PMID Version="1">26516120</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000058" MajorTopicYN="Y">Accidental Falls</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005684" MajorTopicYN="N">Gait</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018737" MajorTopicYN="N">Hand Strength</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007279" MajorTopicYN="N">Injections, Subcutaneous</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018908" MajorTopicYN="N">Muscle Weakness</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055435" MajorTopicYN="N">Myostatin</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<InvestigatorList><Investigator ValidYN="Y"><LastName>Man</LastName>
<ForeName>Zulema</ForeName>
<Initials>Z</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Massari</LastName>
<ForeName>Fabio</ForeName>
<Initials>F</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Bagur</LastName>
<ForeName>Alicia</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Salerni</LastName>
<ForeName>Helena</ForeName>
<Initials>H</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Kurrle</LastName>
<ForeName>Susan</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Davis</LastName>
<ForeName>Chris</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Crotty</LastName>
<ForeName>Maria</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Duque</LastName>
<ForeName>Gustavo</ForeName>
<Initials>G</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Rolland</LastName>
<ForeName>Yves</ForeName>
<Initials>Y</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Lala</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ousset</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Vellas</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Abellan Van Kan</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Faisant</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Villars</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Bonnefoy</LastName>
<ForeName>Marc</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Bourdel-Marchasson</LastName>
<ForeName>Isabelle</ForeName>
<Initials>I</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Cressot</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Duquaret</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Hanon</LastName>
<ForeName>Olivier</ForeName>
<Initials>O</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Bloch</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Seux</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Duron</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Lenoir</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Orvoen</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Plichart</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Riquad</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Blain</LastName>
<ForeName>Hubert</ForeName>
<Initials>H</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Alomene</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Blain</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ferreira</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Schwab</LastName>
<ForeName>Matthias</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Becker</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Igel</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Benzinger</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Keinert</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Schulz</LastName>
<ForeName>Ralf-Joachim</ForeName>
<Initials>RJ</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Goede</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Kilander</LastName>
<ForeName>Lena</ForeName>
<Initials>L</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Lokk</LastName>
<ForeName>Johan</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Surowiak</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Eriksson</LastName>
<ForeName>Bertil</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Waern</LastName>
<ForeName>Ewa</ForeName>
<Initials>E</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Wretborn</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Recknor</LastName>
<ForeName>Christopher</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Williamson</LastName>
<ForeName>Jeffrey</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Binkley</LastName>
<ForeName>Niel</ForeName>
<Initials>N</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Buehring</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Kiel</LastName>
<ForeName>Douglas</ForeName>
<Initials>D</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Schwartz</LastName>
<ForeName>Robert</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Jankowski</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Kohrt</LastName>
<ForeName>M W</ForeName>
<Initials>MW</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Binder</LastName>
<ForeName>Ellen</ForeName>
<Initials>E</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Carr</LastName>
<ForeName>D B</ForeName>
<Initials>DB</Initials>
</Investigator>
</InvestigatorList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year>
<Month>06</Month>
<Day>08</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2015</Year>
<Month>07</Month>
<Day>30</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>08</Month>
<Day>07</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>10</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>10</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>9</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26516121</ArticleId>
<ArticleId IdType="pii">S2213-8587(15)00298-3</ArticleId>
<ArticleId IdType="doi">10.1016/S2213-8587(15)00298-3</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Allemagne</li>
<li>Australie</li>
<li>France</li>
<li>Suisse</li>
<li>États-Unis</li>
</country>
<region><li>Bade-Wurtemberg</li>
<li>District de Stuttgart</li>
<li>Géorgie (États-Unis)</li>
<li>Indiana</li>
<li>Languedoc-Roussillon</li>
<li>Maryland</li>
<li>Massachusetts</li>
<li>Midi-Pyrénées</li>
<li>Missouri (État)</li>
<li>Occitanie (région administrative)</li>
<li>Pennsylvanie</li>
<li>Île-de-France</li>
</region>
<settlement><li>Montpellier</li>
<li>Paris</li>
<li>Pittsburgh</li>
<li>Saint-Louis (Missouri)</li>
<li>Stuttgart</li>
<li>Toulouse</li>
</settlement>
<orgName><li>Université de Pittsburgh</li>
<li>École de médecine (Université Washington de Saint-Louis)</li>
</orgName>
</list>
<tree><country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Becker, Clemens" sort="Becker, Clemens" uniqKey="Becker C" first="Clemens" last="Becker">Clemens Becker</name>
</region>
</country>
<country name="Australie"><noRegion><name sortKey="Lord, Stephen R" sort="Lord, Stephen R" uniqKey="Lord S" first="Stephen R" last="Lord">Stephen R. Lord</name>
</noRegion>
</country>
<country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Studenski, Stephanie A" sort="Studenski, Stephanie A" uniqKey="Studenski S" first="Stephanie A" last="Studenski">Stephanie A. Studenski</name>
</region>
<name sortKey="Ahmad, Qasim I" sort="Ahmad, Qasim I" uniqKey="Ahmad Q" first="Qasim I" last="Ahmad">Qasim I. Ahmad</name>
<name sortKey="Benson, Charles T" sort="Benson, Charles T" uniqKey="Benson C" first="Charles T" last="Benson">Charles T. Benson</name>
<name sortKey="Binder, Ellen F" sort="Binder, Ellen F" uniqKey="Binder E" first="Ellen F" last="Binder">Ellen F. Binder</name>
<name sortKey="Fielding, Roger A" sort="Fielding, Roger A" uniqKey="Fielding R" first="Roger A" last="Fielding">Roger A. Fielding</name>
<name sortKey="Gomez, Elisa V" sort="Gomez, Elisa V" uniqKey="Gomez E" first="Elisa V" last="Gomez">Elisa V. Gomez</name>
<name sortKey="Hochberg, Marc C" sort="Hochberg, Marc C" uniqKey="Hochberg M" first="Marc C" last="Hochberg">Marc C. Hochberg</name>
<name sortKey="Hu, Leijun" sort="Hu, Leijun" uniqKey="Hu L" first="Leijun" last="Hu">Leijun Hu</name>
<name sortKey="Myers, Stephen L" sort="Myers, Stephen L" uniqKey="Myers S" first="Stephen L" last="Myers">Stephen L. Myers</name>
<name sortKey="Pacuch, Kelli R" sort="Pacuch, Kelli R" uniqKey="Pacuch K" first="Kelli R" last="Pacuch">Kelli R. Pacuch</name>
<name sortKey="Recknor, Christopher P" sort="Recknor, Christopher P" uniqKey="Recknor C" first="Christopher P" last="Recknor">Christopher P. Recknor</name>
<name sortKey="Warden, Stuart J" sort="Warden, Stuart J" uniqKey="Warden S" first="Stuart J" last="Warden">Stuart J. Warden</name>
</country>
<country name="Suisse"><noRegion><name sortKey="Ferrari, Serge L" sort="Ferrari, Serge L" uniqKey="Ferrari S" first="Serge L" last="Ferrari">Serge L. Ferrari</name>
</noRegion>
</country>
<country name="France"><region name="Occitanie (région administrative)"><name sortKey="Blain, Hubert" sort="Blain, Hubert" uniqKey="Blain H" first="Hubert" last="Blain">Hubert Blain</name>
</region>
<name sortKey="Benichou, Olivier" sort="Benichou, Olivier" uniqKey="Benichou O" first="Olivier" last="Benichou">Olivier Benichou</name>
<name sortKey="Poiraudeau, Serge" sort="Poiraudeau, Serge" uniqKey="Poiraudeau S" first="Serge" last="Poiraudeau">Serge Poiraudeau</name>
<name sortKey="Rolland, Yves" sort="Rolland, Yves" uniqKey="Rolland Y" first="Yves" last="Rolland">Yves Rolland</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002924 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002924 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:26516121
   |texte=   Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:26516121" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial.

Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki